Stoke Therapeutics (STOK) Return on Capital Employed (2019 - 2026)
Stoke Therapeutics' (STOK) quarterly Return on Capital Employed came in at 47.49% in Q1 2026, down 6048.0% year-on-year from 0.8% in Q1 2025, and down 664.59% quarter-over-quarter from 6.21% in Q4 2025.
Stoke Therapeutics (STOK) Return on Capital Employed (2019 - 2026) Analysis & Trends
Stoke Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 47.49% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 6048.0% year-over-year to 47.49% in Q1 2026; TTM through Mar 2026 was 47.49%, a 6048.0% decrease from a year earlier, with the FY2025 full-year figure at 7.17%, up 4113.0% from the prior year.
- Return on Capital Employed eased to 47.49% in Q1 2026 per STOK's latest filing, from 6.21% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 12.98% in Q1 2025 and bottomed at 65.38% in Q1 2024.
- The 5-year median for Return on Capital Employed is 43.91% (2023), against an average of 34.13%.
- Across the five-year window, Return on Capital Employed jumped 7837 bps in 2025 and plunged 6048 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 44.32% in 2022, then fell by 27 bps to 56.46% in 2023, then gained by 26 bps to 41.82% in 2024, then soared by 85 bps to 6.21% in 2025, then sank by 665 bps to 47.49% in 2026.
- Per Business Quant, the three latest STOK Return on Capital Employed figures stand at 47.49% (Q1 2026), 6.21% (Q4 2025), and 8.22% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | -47.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.49% |
| Dec 31, 2025 | -6.21% |
| Sep 30, 2025 | 8.22% |
| Jun 30, 2025 | 11.28% |
| Mar 31, 2025 | 12.98% |
| Dec 31, 2024 | -41.82% |
| Sep 30, 2024 | -46.80% |
| Jun 30, 2024 | -54.03% |
| Mar 31, 2024 | -65.38% |
| Dec 31, 2023 | -56.46% |
| Sep 30, 2023 | -50.34% |
| Jun 30, 2023 | -45.36% |
| Mar 31, 2023 | -43.91% |
| Dec 31, 2022 | -44.32% |
| Sep 30, 2022 | -39.01% |
| Jun 30, 2022 | -34.60% |
| Mar 31, 2022 | -36.95% |
| Dec 31, 2021 | -37.55% |
| Sep 30, 2021 | -30.79% |
| Jun 30, 2021 | -25.49% |